椎体成形术与假手术治疗急性骨质疏松性椎体压缩骨折:随机假手术对照试验
在荷兰四家社区医院开展的随机双盲假手术对照试验中,180例急性骨质疏松性椎体压缩骨折患者随机接受椎体成形术(n=91)或假手术(n=89)。两组在12个月随访期内VAS评分均较基线显著下降,但组间差异无统计学意义;次要结局(生活质量、Roland-Morris残疾问卷)及镇痛药使用变化亦无显著组间差异。结论:椎体成形术在12个月随访中未带来显著优于假手术的疼痛缓解。
要点
- 椎体成形术与假手术在12个月随访中疼痛缓解无显著差异。
- 两组VAS评分均较基线显著下降,组间差异无统计学意义。
- 次要结局(生活质量、残疾问卷)及镇痛药使用变化无显著组间差异。
核心结论
- 在急性骨质疏松性椎体压缩骨折患者中,经皮椎体成形术在12个月随访内未产生显著优于假手术的疼痛缓解。
研究设计与样本
- 随机、双盲、假手术对照临床试验,2011-15年在荷兰四家社区医院开展,共纳入180例需治疗的急性骨质疏松性椎体压缩骨折患者,随机分为椎体成形术组(n=91)和假手术组(n=89)。
- 两组均接受每个椎弓根局部皮下利多卡因和布比卡因注射;椎体成形术组额外接受骨水泥注入,假手术组模拟该过程。
主要发现
- 椎体成形术组和假手术组在术后所有随访时间点VAS评分较基线均显著下降。
- 组间VAS评分平均差异:基线0.20(95%CI -0.53至0.94),第1天-0.43(-1.17至0.31),第1周-0.11(-0.85至0.63),第1个月0.41(-0.33至1.15),第3个月0.21(-0.54至0.96),第6个月0.39(-0.37至1.15),第12个月0.45(-0.37至1.24);12个月随访期间组间VAS评分变化无统计学显著差异。
- 次要结局(骨质疏松生活质量、Roland-Morris残疾问卷评分变化)组间差异无统计学意义。
- 两组镇痛药(非阿片类、弱阿片类、强阿片类)使用在所有时间点均显著减少,组间无显著差异。
- 椎体成形术组发生2例不良事件:1例呼吸功能不全和1例血管迷走神经反应。
关键数值与推荐
- 临床显著疼痛缓解定义为VAS评分较基线下降1.5分。
临床怎么用
- 对于急性骨质疏松性椎体压缩骨折患者,椎体成形术的疼痛缓解效果与假手术相当,临床决策需权衡其获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether percutaneous vertebroplasty results in more pain relief than a sham procedure in patients with acute osteoporotic compression fractures of the vertebral body. DESIGN: Randomised, double blind, sham controlled clinical trial. SETTING: Four community hospitals in the Netherlands, 2011-15. PARTICIPANTS: 180 participants requiring treatment for acute osteoporotic vertebral compression fractures were randomised to either vertebroplasty (n=91) or a sham procedure (n=89). INTERVENTIONS: Participants received local subcutaneous lidocaine (lignocaine) and bupivacaine at each pedicle. The vertebroplasty group also received cementation, which was simulated in the sham procedure group. MAIN OUTCOME MEASURES: Main outcome measure was mean reduction in visual analogue scale (VAS) scores at one day, one week, and one, three, six, and 12 months. Clinically significant pain relief was defined as a decrease of 1.5 points in VAS scores from baseline. Secondary outcome measures were the differences between groups for changes in the quality of life for osteoporosis and Roland-Morris disability questionnaire scores during 12 months' follow-up. RESULTS: The mean reduction in VAS score was statistically significant in the vertebroplasty and sham procedure groups at all follow-up points after the procedure compared with baseline. The mean difference in VAS scores between groups was 0.20 (95% confidence interval -0.53 to 0.94) at baseline, -0.43 (-1.17 to 0.31) at one day, -0.11 (-0.85 to 0.63) at one week, 0.41 (-0.33 to 1.15) at one month, 0.21 (-0.54 to 0.96) at three months, 0.39 (-0.37 to 1.15) at six months, and 0.45 (-0.37 to 1.24) at 12 months. These changes in VAS scores did not, however, differ statistically significantly between the groups during 12 months' follow-up. The results for secondary outcomes were not statistically significant. Use of analgesics (non-opioids, weak opioids, strong opioids) decreased statistically significantly in both groups at all time points, with no statistically significant differences between groups. Two adverse events occurred in the vertebroplasty group: one respiratory insufficiency and one vasovagal reaction. CONCLUSIONS: Percutaneous vertebroplasty did not result in statistically significantly greater pain relief than a sham procedure during 12 months' follow-up among patients with acute osteoporotic vertebral compression fractures. TRIAL REGISTRATION: ClinicalTrials.gov NCT01200277.
引用
- Firanescu CE, de Vries J, Lodder P, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018. PMID: 29743284. doi:10.1136/bmj.k1551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。